Market remains unimpressed. Still hardly any sales. No regulatory approvals of substance.
$97K revenue for a quarter. Costs $3.3 million.
This company runs more like a Uni research lab not a business. That’s the crux of the problem.
Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-73
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.349K | 269.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 26325098 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 27920545 | 24 |
View Market Depth
| Last trade - 10.06am 22/05/2024 (20 minute delay) ? |
| OSL (ASX) Chart |